Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients

This study has been completed.
Heidelberg University
Astellas Pharma Inc
Hoffmann-La Roche
Aventis Pharmaceuticals
Information provided by:
University of Giessen Identifier:
First received: September 9, 2005
Last updated: May 8, 2007
Last verified: May 2007